PharmaNova, a leader
in nanotechnology-based Drug Delivery Systems, is due to exhibit at the 2009
annual meeting of the American Association of Pharmaceutical Scientists (AAPS)
scheduled in Los Angeles, CA, from November 8 - 12.
The Company will announce new technology breakthroughs in discussions with
visitors to the exhibit. The meeting will be at Los Angeles Convention Center
and the booth location is 2451.
NovaSperse(SM) technology is focused on the formation of stable amorphous nanoparticles
with excellent reproducibility. This technology is being applied to both New
Product Opportunities (NPOs) and Client Sponsored Projects (CSPs).
PharmaNova’s proprietary NovaSperse(SM) technology offers proactive control
of nanoparticle characteristics and is tailored to the unique chemistry of individual
active pharmaceutical ingredients (APIs). PharmaNova’s scientists are
actively advancing the NovaSperse(SM) technology platform towards attaining
a leadership position among nanotechnology-enabled drug delivery companies.
A nanometer is one-billionth of a meter; a human hair is roughly 100,000 nanometers
wide; a human fingernail grows 1 nanometer every second; a sheet of paper is
about 100,000 nanometers thick.
PharmaNova Inc. is a privately held, specialty pharmaceutical company founded
on the re-positioning and enhancement of known drugs using its proprietary NovaSperse(SM)
nanoparticle technology platform and other complementary drug delivery and formulation
technologies. We address low-risk, fast-to-market products in areas of clear
medical need and generate revenue from partnering and licensing strategies with
commercialization partners worldwide. PharmaNova also provides contractual services
for the NovaSperse(SM)-based formulation of client-owned APIs. PharmaNova’s
pipeline includes a (partnered) non-hormonal treatment for menopausal hot flashes
and topical anti-infective and ophthalmic new product opportunities. PharmaNova
and Altacor of Cambridge, England, have formed a strategic alliance to develop
and commercialize a series of new prescription ophthalmic medical products based
on PharmaNova’s proprietary NovaSperse(SM) nanoparticle technology.
Posted September 30th, 2009
